Regencell Bioscience Holdings Ltd. (RGC): Price and Financial Metrics
GET POWR RATINGS... FREE!
RGC Stock Price Chart Interactive Chart >
RGC Price/Volume Stats
|Current price||$31.44||52-week high||$48.29|
|Prev. close||$31.00||52-week low||$20.00|
|Day high||$33.82||Avg. volume||13,086|
|50-day MA||$30.45||Dividend yield||N/A|
|200-day MA||$31.22||Market Cap||397.46M|
Regencell Bioscience Holdings Ltd. (RGC) Company Bio
Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.
Most Popular Stories View All
RGC Latest News Stream
|Loading, please wait...|
RGC Latest Social Stream
View Full RGC Social Stream
Latest RGC News From Around the Web
Below are the latest news stories about REGENCELL BIOSCIENCE HOLDINGS LTD that investors may wish to consider to help them evaluate RGC as an investment opportunity.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
By Brad Sorensen, CFA NASDAQ:RGC Traditional “western” medicine has made amazing advances and is one of the great innovations in history, but, unfortunately, there are still many conditions afflicting people that western medicine hasn’t been able to treat with any great effectiveness. It’s in instances like these that it can be beneficial to look to a medical approach that’s been around for over
One Regencell Bioscience Holdings Limited (NASDAQ:RGC) insider upped their stake by 1.4% in the previous year
Insiders were net buyers of Regencell Bioscience Holdings Limited's ( NASDAQ:RGC ) stock during the past year. That is...
81% of Regencell Bioscience Holdings Limited (NASDAQ:RGC) is owned by insiders, and they've been buying recently
Every investor in Regencell Bioscience Holdings Limited ( NASDAQ:RGC ) should be aware of the most powerful shareholder...
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
HONG KONG, September 12, 2022--Regencell Bioscience Holdings Limited (Nasdaq: RGC) ("Regencell") today announced its interim results from its second efficacy trial.
RGC Price Returns